Debt-free Balance SheetZero reported debt materially reduces solvency and fixed-payment risk, giving management flexibility to prioritize R&D, regulatory milestones or selective commercialization over the next 2–6 months. This structural balance-sheet strength lowers near-term bankruptcy tail risk while the business scales.

Substantial Equity BufferA meaningful equity base (~SEK 75.8M) provides a durable financial cushion to absorb ongoing losses and fund operations or clinical work. Over a multi-month horizon this equity reduces immediate financing pressure and extends runway for commercialization or regulatory progress.

Exposure To Diagnostic Medical DevicesOperating in diagnostics/medical devices aligns the company with long-term structural demand (aging populations, need for better diagnostics). This industry exposure offers durable market tailwinds that can support revenue generation once clinical validation and commercialization milestones are achieved.

Bears Say

Effectively Zero RevenuePersistent absence of revenue across multiple years indicates the company has yet to validate commercial product-market fit. Over a 2–6 month horizon this structural shortfall means operations rely on financing, delaying self-sustaining growth and raising execution risk for scaling activities.

Ongoing Operating LossesSizable recurring operating losses (~SEK 11M in 2025) are a structural drain on equity and require external funding or dilution if sustained. Such persistent losses limit the company's ability to reinvest in commercialization without continual capital raises, increasing execution and financing risk.

Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the core business is not self-funding. This structural cash burn necessitates continued external financing to cover operations and R&D, constraining strategic options and increasing dilution or refinancing risk over the coming months.

Neola Medical AB News

Neola Medical’s Neonatal Lung Monitor Clears Key Pilot Milestone

Neola Medical AB ($SE:NEOLA) announced an update on their ongoing clinical study. The clinical pilot study “Clinical Pilot...

1d ago

NEOLA

Neola Medical’s Pivotal Study: A Game Changer in Neonatal Lung Monitoring?

Neola Medical AB (($SE:NEOLA)) announced an update on their ongoing clinical study. Study Overview: Neola Medical AB is...

5M ago

NEOLA

NEOLA FAQ

What was Neola Medical AB’s price range in the past 12 months?

Neola Medical AB lowest stock price was kr0.60 and its highest was kr3.04 in the past 12 months.

What is Neola Medical AB’s market cap?

Neola Medical AB’s market cap is kr60.80M.

When is Neola Medical AB’s upcoming earnings report date?

Neola Medical AB’s upcoming earnings report date is May 27, 2026 which is in 68 days.

How were Neola Medical AB’s earnings last quarter?

Neola Medical AB released its earnings results on Feb 12, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.034.

Is Neola Medical AB overvalued?

According to Wall Street analysts Neola Medical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neola Medical AB pay dividends?

Neola Medical AB does not currently pay dividends.

What is Neola Medical AB’s EPS estimate?

Neola Medical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neola Medical AB have?

Neola Medical AB has 77,950,230 shares outstanding.

What happened to Neola Medical AB’s price movement after its last earnings report?

Neola Medical AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.267%.

Which hedge fund is a major shareholder of Neola Medical AB?

Currently, no hedge funds are holding shares in SE:NEOLA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Neola Medical AB

Neola Medical AB (publ) develops medical equipment for continuous monitoring of the lungs of premature babies. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provides intensive care and healthier lives for preterm born infants. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.